REDWOOD CITY, Calif.–(BUSINESS WIRE) –– May 30, 2018 — Atreca, Inc., a
biotechnology company focused on developing novel therapeutics based on a deep
understanding of the human immune response, announced today that John A. Orwin,
President and Chief Executive Officer, will present at the Jefferies 2018 Global
Healthcare Conference on Wednesday, June 6, 2017 at 2:30 p.m. Eastern Time in New
York, NY. Mr. Orwin will provide an overview of Atreca’s technologies, programs and
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn
from human immune responses, including effective anti-cancer immune responses. We
are able to measure and analyze the structure of clinically relevant immune responses
to identify the antibodies, T cell receptors (TCRs), and targets that are key to successful
treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® (IRC™)
technology profiles a patient’s immune response at the single-cell level at very high
throughput essentially without bias or error. This approach enables the identification,
generation, and analysis of functional human antibody and TCR sequences from single
B and T cells without prior knowledge of antigen. Atreca is advancing a pipeline of
candidates designed to engage the human immune response in oncology and other
indications, thus driving better therapeutic outcomes. For more information on Atreca,
please visit www.atreca.com.
EVP and Chief Financial Officer
Justin Jackson, 212-213-0006, ext. 327
Alex Gray, 212-213-0006, ext. 355
Source: Atreca, Inc.